Strategic partnerships ivWatch has recently partnered with Aon to quantify clinical and financial impact of IV injuries and model ROI, signaling openness to collaboration with risk, insurance, and healthcare systems stakeholders. Leverage these partnership signals to approach payer, risk management, and hospital procurement teams with ROI-driven value propositions.

Clinical impact focus The firm’s FDA-cleared CE-marked device targets early detection of IV infiltrations and extravasations, addressing a top patient safety concern and underreported harms. Use this to tailor conversations around patient safety metrics, quality improvement programs, and favorable risk reduction narratives for hospital buyers.

Regulatory credibility The dual FDA clearance and CE marking provide regulatory credibility across U.S. and international markets, aiding market entry discussions with hospital networks, VA systems, and international clinics seeking compliant IV safety solutions.

Medical device traction Revenue in the low to mid range with substantial funding and a growing leadership footprint indicates scale-up potential. Target mid-sized healthcare systems and specialty clinics that perform high volumes of IV therapy and face cost of adverse events to unlock larger deployments.

Recognition and storytelling Industry awards and positive press around patient stories (DANDA awards, Virginia manufacturing honors) create social proof for sales outreach. Use case studies and impact narratives in conversations with clinical champions and procurement to reinforce value and adoption potential.